Skip to main content

Data highlights

The Data Highlights section showcases recently published datasets on COVID-19 and SARS-CoV-2 by researchers affiliated with a Swedish research institute. The goal is to highlight openly shared data that can potentially be used by many other researchers to make further discoveries. If you have published or are about to publish data that you think should be highlighted in this section, you are welcome to send us a suggestion.

Host factor interaction between human G3BP proteins and SARS-CoV-2 N-protein could represent an antiviral target
Host factor interaction between human G3BP proteins and SARS-CoV-2 N-protein could represent an antiviral target

2021-11-24

Kruse and Benz et al. describe a scalable method of investigating virus-host interactions that can be used as a means of identifying potential targets for novel antiviral drugs. All data from the study have been shared publicly.
Read more

Drug repurposing identifies Fostamatinib as a drug with potentially high efficacy in COVID-19 treatment
Drug repurposing identifies Fostamatinib as a drug with potentially high efficacy in COVID-19 treatment

2021-11-19

Recent study finds that drug repurposing can offer an average of an 11-fold increase in disease coverage and demonstrates its value for COVID-19. All data and code that support the findings have been made publicly available.
Read more

Clues to the genetic factors underlying greater susceptibility to severe COVID-19 in men
Clues to the genetic factors underlying greater susceptibility to severe COVID-19 in men

2021-11-03

The COVID Human Genetic Efforts consortium published a study on genetic factors underlying greater susceptibility to the severe COVID-19 in men. Relevant RNA-seq data were shared in Gene Expression Omnibus (GEO).
Read more

Reliable profiling of IgG and IgM levels in home-sampled dried blood spots
Reliable profiling of IgG and IgM levels in home-sampled dried blood spots

2021-10-18

Roxhed et al. demonstrate how self sampling at home can be effective by profiling IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots. Metadata records and the analysis scripts used in the study are shared.
Read more

Metabolic perturbation of SARS-CoV-2 as a potential future therapeutic target
Metabolic perturbation of SARS-CoV-2 as a potential future therapeutic target

2021-10-07

Krishnan et al. showed that the SARS-CoV-2 virus can use and rewire metabolic pathways to their benefit in replication. Their findings indicate that host metabolic perturbation could be an attractive strategy to limit replication. Code and data from the study have been shared pubicly.
Read more

Human genetic mapping can provide insight about COVID-19 pathogenesis and drug development
Human genetic mapping can provide insight about COVID-19 pathogenesis and drug development

2021-08-10

Researchers in the COVID-19 Host Genetics initiative performed genome-wide association meta-analyses to examine the loci involved in the variation of COVID-19 disease severity and susceptibility between individuals. The data and code used in the project have been made available.
Read more

New phenomics method for antiviral drug discovery may help to fight COVID-19
New phenomics method for antiviral drug discovery may help to fight COVID-19

2021-08-02

Rietdijk and colleagues used a new phenomics approach to aid in the discovery of both novel drugs and drugs that could potentially be repurposed to fight COVID-19. Both data and code are published.
Read more

Interferon signatures in SARS-CoV-2 infected liver cells could provide knowledge for new antiviral therapies
Interferon signatures in SARS-CoV-2 infected liver cells could provide knowledge for new antiviral therapies

2021-07-06

Chen and Saccon et al. used a proteomics-based approach to study how SARS-CoV-2 infection affected Type-1 interferon signalling in liver cells. Both data and code are published.
Read more

Cost-effective COVseq method could be used for large-scale genomic surveillance of VOCs
Cost-effective COVseq method could be used for large-scale genomic surveillance of VOCs

2021-07-01

Simonetti, Zhang, and Harbers et al. have shared a cost-effective, scalable and versatile method (alongside associated data and code) that could facilitate large-scale genomic surveillance of variants of concern (VOCs).
Read more

Quantitative proteomic provides important knowledge about cellular response against SARS CoV-2
Quantitative proteomic provides important knowledge about cellular response against SARS CoV-2

2021-05-19

Saccon and colleagues studied changes in protein abundance caused by SARS-CoV-2 virus in susceptible cell lines using quantitative proteomics. All proteomics were made data openly available in different repositories.
Read more

Proteomic profiling in COVID-19 patients as biomarkers to monitor disease severity
Proteomic profiling in COVID-19 patients as biomarkers to monitor disease severity

2021-04-13

Recent study examined a large number of inflammatory, immune response, cardiovascular, and neurological markers in the blood of patients variously impacted by COVID-19. Data and analysis code were shared in public repositories.
Read more

Swedish COVID-19 symptom data contribute to accelerating research about pandemic
Swedish COVID-19 symptom data contribute to accelerating research about pandemic

2021-03-29

COVID Symptom Study Sweden collects data through a smartphone app to investigate prevalence, risk factors, and symptoms associated with COVID-19. To date, over 200.000 volunteers have enrolled in the study.
Read more

Neanderthal gene protecting against severe COVID-19 could be potential new drug target
Neanderthal gene protecting against severe COVID-19 could be potential new drug target

2021-03-10

A new study largely relying on existing data re-use identified circulating proteins influencing COVID-19 susceptibility and severity. Based on these results, work on repurposing relevant existing drugs work can now be launched.
Read more

Bevacizumab treatment beneficial for patients with severe COVID-19
Bevacizumab treatment beneficial for patients with severe COVID-19

2021-02-18

A recently published clinical study investigating bevacizumab, a humanized anti-VEGF monoclonal antibody, offers promising results in fighting severe COVID-19. Treatment progress data and analysis code were shared publicly.
Read more

Nanobodies promising new therapeutics for treatment of SARS CoV-2
Nanobodies promising new therapeutics for treatment of SARS CoV-2

2021-02-16

A recently published study characterizes the mechanisms by which nanobodies neutralize or prevent of infection in molecular detail. Crystallographic coordinates, cryo-EM density maps, and atomic coordinates were deposited to public databases.
Read more

Mechanism of entry used by human species D adenoviruses proving important for COVID-19 vaccine development
Mechanism of entry used by human species D adenoviruses proving important for COVID-19 vaccine development

2021-01-18

New study identifies a noncanonical entry mechanism used by human adenoviruses, important for development of adenovirus-based vaccine vectors. The reported X-ray structural data was made available through the Protein Data Bank.
Read more

A novel approach to discover and characterize broad-spectrum antivirals
A novel approach to discover and characterize broad-spectrum antivirals

2020-12-18

Newly discovered antiviral compounds showed broad-range antiviral activity against pathogenic RNA viruses such as SARS-CoV-2. The authors share data freely in open repositories.
Read more

Pathogenesis of hyperinflammatory syndrome associated with COVID-19 in children
Pathogenesis of hyperinflammatory syndrome associated with COVID-19 in children

2020-12-07

Multiple autoantibodies and specific cytokines could be involved in the pathogenesis of MIS-C associated with COVID-19. Data and code made available in open repositories.
Read more

An alpaca-derived nanobody can potently neutralize SARS-CoV-2
An alpaca-derived nanobody can potently neutralize SARS-CoV-2

2020-11-27

Leo Hanke and colleagues identified a SARS-CoV-2 RBD-specific single domain antibody fragment, Ty1, that potently neutralizes the virus. Ty1 should now be further investigated as a candidate for antiviral therapy.
Read more

Synthetic nanobodies are easy to produce and can effectively neutralize SARS-CoV-2
Synthetic nanobodies are easy to produce and can effectively neutralize SARS-CoV-2

2020-11-24

Recently published study demonstrates that it is possible to select highly specific binders with neutralizing activity against SARS-CoV-2 from a synthetic nanobody library in a short timeframe.
Read more

MAIT cell activation and dynamics studied in relation to COVID-19 disease severity
MAIT cell activation and dynamics studied in relation to COVID-19 disease severity

2020-11-18

Tiphaine Parrot and colleagues studied changes in conventional and unconventional T cell subsets in patients with various disease severity using flow cytometry. The results were published along with the data.
Read more

Crystal structure of SARS CoV-2 nsp-10 - a potential drug target for COVID-19
Crystal structure of SARS CoV-2 nsp-10 - a potential drug target for COVID-19

2020-11-03

A study by Rogstam and colleagues published along with the crystal structure of SARS CoV-2 non-structural protein 10 in the Protein Data Bank provides a starting point for structure-guided drug discovery and design.
Read more

Bayesian model for estimating the impact of mobility patterns on COVID-19 infection
Bayesian model for estimating the impact of mobility patterns on COVID-19 infection

2020-10-23

Patrick Bryant and Arne Elofsson shared code and instructions for modelling COVID-19 development using MCMC simulations based on mobile phone mobility data from Google mobility reports.
Read more

First study using data collected as part of the large-scale serology testing at SciLifeLab published
First study using data collected as part of the large-scale serology testing at SciLifeLab published

2020-10-15

This study used only a fraction of the large volume of serology data continuously collected by the ScilifeLab Autoimmunity and Serology profiling facility.
Read more

Data-driven research shows that Neanderthal gene connected to severity of COVID-19
Data-driven research shows that Neanderthal gene connected to severity of COVID-19

2020-10-02

Study by Hugo Zeberg and Svante Pääbo fully based on openly available data published open access in Nature.
Read more

Method circumventing RNA extraction in RT-PCR COVID-19 testing published along with data
Method circumventing RNA extraction in RT-PCR COVID-19 testing published along with data

2020-10-01

Study by Björn Reinius and co-workers published open access in Nature Communications along with source data and the computational code.
Read more